Skip to main content

Table 1 General characteristics of study population at enrolment according to study arms

From: Hepatic safety of repeated treatment with pyronaridine‐artesunate versus artemether–lumefantrine in patients with uncomplicated malaria: a secondary analysis of the WANECAM 1 data from Bobo-Dioulasso, Burkina Faso

Parameters Pyronaridine-artesunate
(PA), N = 224
Artemether–lumefantrine
(AL), N = 296
Sex (male), n (%) 95 (42.41) 133 (44.93)
Age, mean ± SD (in year) 8.96 ± 6.52 9.29 ± 7.56
Age groups (in year), n (%)   
 ≤ 5 58 (25.9) 84 (28.38)
 > 5 to ≤ 15 138 (61.61) 171 (57.77)
 > 15 28 (12.5) 41 (13.85)
Weight, mean ± SD 25.99 ± 14.46 26.33 ± 14.70
Height, mean ± SD 124.47 ± 24.86 124.76 ± 25.89
Major symptoms, n (%)   
 Fever 224 (100) 296 (100)
 Headache 180 (80.36) 216 (72.97)
 Anorexia 123 (54.91) 135 (45.61)
 Vomiting 112 (50.00) 126 (42.57)
 Abdominal pain 133 (59.38) 159 (53.72)
Plasmodium species, n (%)   
 P. falciparum 222 (99.11) 291 (98.31)
 P. malariae 1 (0.45) 4 (1.35)
 P. ovale 1 (0.45) 1 (0.34)
 P. falciparum density, mean ± SD § 16,218 ± 9.50 14,739 ± 9.18
ALT (IU /L), mean ± SD 23.63 ± 11.16 23.61 ± 15.09
AST (IU /L), mean ± SD 29.16 ± 14.83 29.37 ± 15.56
ALP (IU/L), mean ± SD 225.52 ± 95.93 223.98 ± 92.82
Total bilirubin (mg/dL), mean ± SD 1.38 ± 1.06 1.24 ± 0.91
Direct bilirubin (mg/dL), mean ± SD 0.43 ± 0.29 0.41 ± 0.27
Haemoglobin (g/dL), mean ± SD 10.69 ± 1.48 10.49 ± 1.51
  1. SD: Standard deviation; CI: Confidence interval; P: Plasmodium; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; p: p-value; IU/L: International Units per litre; mg/dl: milligrams per decilitre; g/dl: grams per decilitre; §: geometric mean